Ernexa Therapeutics Inc. (ERNA) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jul 22, 2026
Ernexa Therapeutics Inc. (ERNA)
A forensic read on Ernexa Therapeutics Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-147.2
Altman Z-score
Clean
Earnings quality
5
Forensic signals
-586.6%
ROE
755.9%
Revenue growth
Financial health / Altman Z-score above is based on book value, not market value — this free snapshot doesn't pull live market data. Treat it as a rough read, not the final word.
Ernexa Therapeutics Inc. earns a F (Poor — capital at risk) forensic quality grade, and its Altman Z-score is -147.2, placing it in the Distress zone (based on book value, not market value, since this free snapshot doesn't pull live market data — treat this zone as a rough read, not the final word). 5 forensic signals were flagged in its latest SEC filings, led by accruals ratio (% of noa).
What the filings flag
n/m (sign flip)
FY2024→FY2025
Accruals ratio (% of NOA).Net operating assets flipped from negative to positive FY2024→FY2025 (FY2024 $-0.0M to FY2025 $+2.4M) — the standard accruals ratio divides by the average of the two, which collapses toward zero right as the sign changes, so the resulting percentage is a denominator artifact, not a real accrual measurement. Treat this as a structural balance-sheet shift to understand on its own terms rather than a clean or dirty accruals read.
38d DSO
FY2019→FY2020
Receivables vs revenue.Days sales outstanding moved from 22 to 38 days FY2019→FY2020 (receivables -100% vs revenue -71%). Receivables are creeping up relative to sales — watch the trend.
n/m (stock split)
FY2022–FY2025
Share count (stock split).Diluted share count changed +107% over the last 3 years to FY2025, but that includes a large one-time change around FY2023 consistent with a stock split or reverse split, not gradual buybacks or issuance — a split changes the count with NO effect on any holder's proportional ownership, so the raw +27.4%/yr figure isn't a real buyback/dilution read here.
261% of rev
FY2024
Stock-based comp load.Stock-based compensation ran 261% of revenue in FY2024 — about $1.67 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
$662,000
FY2020–FY2020
Goodwill impairments.
Key fundamentals
Latest Revenue$582,000.00
Revenue Growth YoY+755.9%
Net Margin-7652.7%
Free Cash Flow$-7.1M
Return on Equity-586.6%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Ernexa Therapeutics Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about ERNA's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
Data from SEC EDGAR public filings · metrics as of Jul 22, 2026. Forensic signals flag probability, not certainty.
Took $662,000 of goodwill writedowns across 1 year (FY2020 ($662,000)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.